Investigational Drug Information for INC280
✉ Email this page to a colleague
What is the drug development status for INC280?
INC280 is an investigational drug.
There have been 38 clinical trials for INC280.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 22nd 2021.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Novartis.
There are seventy-five US patents protecting this investigational drug and one international patent.
Summary for INC280
| US Patents | 75 |
| International Patents | 1,086 |
| US Patent Applications | 425 |
| WIPO Patent Applications | 323 |
| Japanese Patent Applications | 122 |
| Clinical Trial Progress | Phase 2 (2021-09-22) |
| Vendors | 79 |
Recent Clinical Trials for INC280
| Title | Sponsor | Phase |
|---|---|---|
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | National Cancer Institute (NCI) | Phase 2 |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Southwest Oncology Group | Phase 2 |
| Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | Novartis | Phase 1 |
Clinical Trial Summary for INC280
Top disease conditions for INC280
Top clinical trial sponsors for INC280
US Patents for INC280
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| INC280 | ⤷ Try a Trial | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Try a Trial |
| INC280 | ⤷ Try a Trial | Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma | Massachusetts Eye and Ear Infirmary (Boston, MA) | ⤷ Try a Trial |
| INC280 | ⤷ Try a Trial | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Try a Trial |
| INC280 | ⤷ Try a Trial | Methods of treating pediatric cancers | Loxo Oncology, Inc. (Stamford, CT) | ⤷ Try a Trial |
| INC280 | ⤷ Try a Trial | Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers | SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) YONSEI UNIVERSITY, UNIVERSITY-INDUSTRY FOUNDATION (UIF) (Seoul, KR) | ⤷ Try a Trial |
| INC280 | ⤷ Try a Trial | Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| INC280 | ⤷ Try a Trial | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INC280
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| INC280 | European Patent Office | EP3131552 | 2034-04-16 | ⤷ Try a Trial |
| INC280 | Spain | ES2823756 | 2034-04-16 | ⤷ Try a Trial |
| INC280 | Japan | JP2017514806 | 2034-04-16 | ⤷ Try a Trial |
| INC280 | Japan | JP2019070012 | 2034-04-16 | ⤷ Try a Trial |
| INC280 | Japan | JP2021059548 | 2034-04-16 | ⤷ Try a Trial |
| INC280 | Japan | JP6838085 | 2034-04-16 | ⤷ Try a Trial |
| INC280 | New Zealand | NZ629860 | 2034-04-16 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
